Pulmonary Thromboembolism in a Soccer Player after COVID-19 Infection: Case Report  

作　　者：Paulo Roberto Santos-Silva Júlia Maria D'Andrea Greve Fernando Ribeiro Cristian Alvarez Fernanda Firmino Giachetta Marcelo Hiro Akiyoshi Ichige Guilherme Veiga Guimarães 

机构地区：[1]Instituto de Ortopedia e Traumatologia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo,São Paulo,05403-010,Brasil [2]Institute of Biomedicine(iBiMED),School of Health Sciences,University of Aveiro,Aveiro,3810-193,Portugal [3]Exercise and Rehabilitation Sciences Laboratory,School of Physical Therapy,Faculty of Rehabilitation Sciences,Universidad Andres Bello,Concepcion,8370035,Chile [4]Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo,São Paulo,05403-000,Brasil

出　　处：《Journal of Sports Science》2023年第1期1-6,共6页运动科学（英文版）

摘　　要：Background:Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),which causes COVID-19,is characterized by an increased risk of thromboembolic events.However,more than 80%of patients are asymptomatic or have only minor/mild symptoms.In addition,diagnosing thromboembolism in athletes is challenging,as symptoms can be confused with musculoskeletal complaints or physical deconditioning.Case presentation:Here we report the case of a previously healthy 34-year-old professional soccer player with COVID-19 infection and genetic predisposition to thrombosis.At baseline,he was fit,had no symptoms,did not require hospital admission due to a COVID-19 infection,and was started on a five-day course of azithromycin and dexamethasone therapy.After 10 days of returning to professional activity,he developed pulmonary embolism following a COVID-19 infection during a physical exercise session.Angiotomography showed positive acute and subacute pulmonary thromboembolism,being treated with rivaroxaban 20 mg/day continuously.The shared decision-making between the medical team and the athlete was not to return to professional soccer,given the quantifiable risk.Considerations:This case illustrates the potential risk of COVID-19-induced pulmonary thromboembolism,which can be affected by genetic predisposition and dexamethasone therapy or the consequences of COVID-19.In this clinical period,the athlete’s condition may be overlooked due to the masking effects of other clinical conditions and physical abnormalities.The residual effects of COVID-19 disease can appear late,requiring caution and follow-up by the medical team before releasing the athlete into a training program.

关 键 词：COVID-19 SARS-CoV-2 pulmonary embolism ANTICOAGULATION athlete. 

分 类 号：R73[医药卫生—肿瘤]